Literature DB >> 13699407

Rescinnamine in treatment of hypertension in hospital clinic and in general practice.

R FIFE, J C MACLAURIN, J H WRIGHT.   

Abstract

Entities:  

Keywords:  HYPERTENSION/therapy; RAUWOLFIA/therapy

Mesh：

Substances：

Year:  1960        PMID： 13699407      PMCID： PMC2098607          DOI： 10.1136/bmj.2.5216.1848

Source DB:  PubMed          Journal:  Br Med J        ISSN： 0007-1447


× No keyword cloud information.
  10 in total

1.  Diagnosis and treatment of essential hypertension.

Authors:  R W TURNER
Journal:  Lancet       Date:  1959-05-09       Impact factor: 79.321

2.  Comparison of rescinnamine and reserpine as hypotensive agents.

Authors:  F H SMIRK; E G McQUEEN
Journal:  Lancet       Date:  1955-07-16       Impact factor: 79.321

3.  The response to rescinnamine administered parenterally and orally for the treatment of hypertension.

Authors:  R L HERSHBERGER; E W DENNIS; J H MOYER
Journal:  Am J Med Sci       Date:  1956-05       Impact factor: 2.378

4.  The out-patient department and the general practitioner.

Authors:  J FRY
Journal:  R Soc Health J       Date:  1958 Jul-Aug

5.  Therapeutic value and limitations of an ataractic drug (rescinnamine).

Authors:  S S WINTON
Journal:  Int Rec Med Gen Pract Clin       Date:  1957-12

6.  Treatment of hypertension in out-patients; the initial assessment, and the effect of reserpine.

Authors:  R FIFE; J P PATON; W G WHYTE
Journal:  Scott Med J       Date:  1958-04       Impact factor: 0.729

7.  Drug therapy (Rauwolfia) of hypertension. II. A comparative study of different extracts of Rauwolfia when each is used alone (orally) for therapy of ambulatory patients with hypertension.

Authors:  J H MOYER; E DENNIS; R FORD
Journal:  AMA Arch Intern Med       Date:  1955-10

8.  Treatment of arterial hypertension with rescinnamine, a new alkaloid isolated from Rauwolfia serpentina.

Authors:  G LEMIEUX; A DAVIGNON; J GENEST
Journal:  Can Med Assoc J       Date:  1956-01-15       Impact factor: 8.262

9.  Pharmacological studies with rescinnamine, a new alkaloid isolated from Rauwolfia serpentina.

Authors:  G CRONHEIM; W BROWN; J CAWTHRONE; M I TOEKES; J UNGARI
Journal:  Proc Soc Exp Biol Med       Date:  1954-05

10.  The threshold of age.

Authors:  J M MACKINTOSH
Journal:  Lancet       Date:  1954-05-15       Impact factor: 79.321
  10 in total
  3 in total

1.  Clinical trial of methoserpidine in general practice.

Authors:  D L JONES; A M MICHAEL; J P OMMER
Journal:  Br Med J       Date:  1961-12-30

Review 2.  Research progress in the biological activities of 3,4,5-trimethoxycinnamic acid (TMCA) derivatives.

Authors:  Zefeng Zhao; Huanhuan Song; Jing Xie; Tian Liu; Xue Zhao; Xufei Chen; Xirui He; Shaoping Wu; Yongmin Zhang; Xiaohui Zheng
Journal:  Eur J Med Chem       Date:  2019-04-06       Impact factor: 6.514

3.  Computational and synthetic studies towards improving rescinnamine as an inducer of MSH2-dependent apoptosis in cancer treatment.

Authors:  ElShimaa M N AbdelHafez; Andrew Diamanduros; Lacramioara Negureanu; Yan Luy; J Hayley Bean; Katherine Zielke; Brittany Crowe; Aksana Vasilyeva; Jill E Clodfelter; Omar M Aly; Gamal El-Din A A Abuo-Rahma; Karin D Scarpinato; Freddie R Salsbury; S Bruce King
Journal:  Mol Cancer Biol       Date:  2013
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.